These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 33751503)
21. Drug treatment of obsessive-compulsive disorder. Kellner M Dialogues Clin Neurosci; 2010; 12(2):187-97. PubMed ID: 20623923 [TBL] [Abstract][Full Text] [Related]
22. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Fineberg NA; Reghunandanan S; Brown A; Pampaloni I Aust N Z J Psychiatry; 2013 Feb; 47(2):121-41. PubMed ID: 23125399 [TBL] [Abstract][Full Text] [Related]
23. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses]. Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085 [TBL] [Abstract][Full Text] [Related]
24. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Brakoulias V; Stockings E Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669 [TBL] [Abstract][Full Text] [Related]
28. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Kim CH; Cheon KA; Koo MS; Ryu YH; Lee JD; Chang JW; Lee HS Neuropsychobiology; 2007; 55(3-4):156-62. PubMed ID: 17657168 [TBL] [Abstract][Full Text] [Related]
29. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density. Wolmarans de W; Brand L; Stein DJ; Harvey BH Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013 [TBL] [Abstract][Full Text] [Related]
30. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity. Brakoulias V Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422 [TBL] [Abstract][Full Text] [Related]
31. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. Denys D; van Megen H; Westenberg H J Clin Psychiatry; 2002 Aug; 63(8):700-3. PubMed ID: 12197450 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice. Grados MA; Riddle MA J Clin Child Psychol; 2001 Mar; 30(1):67-79. PubMed ID: 11294079 [TBL] [Abstract][Full Text] [Related]
33. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. Stein DJ; Bouwer C; Hawkridge S; Emsley RA J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814 [TBL] [Abstract][Full Text] [Related]
35. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Keuneman RJ; Pokos V; Weerasundera R; Castle DJ Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020 [TBL] [Abstract][Full Text] [Related]
38. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Fineberg NA; Brown A; Reghunandanan S; Pampaloni I Int J Neuropsychopharmacol; 2012 Sep; 15(8):1173-91. PubMed ID: 22226028 [TBL] [Abstract][Full Text] [Related]
39. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Dold M; Aigner M; Lanzenberger R; Kasper S Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229 [TBL] [Abstract][Full Text] [Related]
40. A review of pharmacologic treatments for obsessive-compulsive disorder. Kaplan A; Hollander E Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]